Pharmaceuticals, Biotechnology and Life Sciences
New data from the DESTINY-Breast01 trial reinforce the efficacy of ENHERTU® in HER2-positive metastatic breast cancer, while the new data from the SERENA-1 Phase I trial show strong efficacy and safety profile for next-generation oral SERD AZD9833 in HR-positive advanced breast cancer.
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union (EU) for the 1st-line maintenance treatment with bevacizumab of patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer.
AstraZeneca on Friday reported several clinical results from its studies, including Imfinzi and Enhertu, with meaningful outcomes.
AstraZeneca has concluded the first agreements for at least 400 million doses and has secured total manufacturing capacity for one billion doses so far and will begin first deliveries in September 2020.
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
Te U.S. Food and Drug Administration (FDA) approved the myChoice CDx test for use as a companion diagnostic by healthcare professionals to identify certaikn advanced ovarian cancer patients.
AstraZeneca’s and Merck’s Olaparib, Lynparza has been approved in US as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer, the companies said Monday in a press release.
Daiichi Sankyo and AstraZeneca’s Enhertu trastuzumab has been granted Breakthrough Therapy Designation (BTD) in the U.S. for the treatment of patients with HER2 positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received two or more prior regimens including trastuzumab.
AstraZeneca has updated use of Lokelma based on data from Phase IIIb DIALIZE trial.
AstraZeneca and Merck revealed further positive results from the Phase 3 PROfound trial evaluating LYNPARZA in men with metastatic castration-resistant prostate cancer (mCRPC).